Contact us
+98-21-66348560

All posts by: Roham Deyhimfar

  1. Home
  2. Author: Roham Deyhimfar
2024-04-16
in Urology

First-Line Immuno-Oncology Therapies Up Survival in RCC With Brain Metastases

First-Line Immuno-Oncology Therapies Up Survival in RCC With Brain Metastases First-line immuno-oncology (IO)-based regimens and intensive focal therapies are associated with significantly prolonged overall survival (OS) among patients with brain metastases from renal cell carcinoma (RCC), new findings suggest. In a real-world study, median OS was 32.7 months for patients who received first-line IO-based combination […]

Continue reading
2024-04-14
in Urology

Erectile Dysfunction Drugs Plus Nitrates Tied to CV Morbidity and Mortality Risk

Erectile Dysfunction Drugs Plus Nitrates Tied to CV Morbidity and Mortality Risk Among men with stable coronary artery disease (CAD), the use of phosphodiesterase-5 inhibitors (PDE5is), or erectile dysfunction drugs, combined with nitrate medication may increase the risk for cardiovascular morbidity and mortality, according to study findings published in the Journal of the American College of […]

Continue reading
2024-04-11
in Urology

Risk for Gout Flares With Initiation of Urate-Lowering Therapy Varies by Drug/Dose

Risk for Gout Flares With Initiation of Urate-Lowering Therapy Varies by Drug/Dose The introduction of urate-lowering therapy (ULT) can affect the risk for gout flares, with fewer flares observed when less intensive treatment and flare prophylaxis were used. These study findings were published in Arthritis Care & Research.Researchers conducted a systematic review and meta-analysis to examine […]

Continue reading
2024-04-04
in Bladder cancer

Neoadjuvant Pembrolizumab for MIBC Improves Outcomes

Neoadjuvant Pembrolizumab for MIBC Improves Outcomes Patients with localized muscle-invasive bladder cancer (MIBC) may experience greater pathologic response when treated with neoadjuvant pembrolizumab rather than neoadjuvant cisplatin-based chemotherapy or upfront radical cystectomy (RC). The finding is from separate retrospective analyses of cisplatin-eligible and cisplatin-ineligible patients. Among 458 cisplatin-ineligible patients treated from October 2005-2020 at Moffitt Cancer Center […]

Continue reading
High Plant Intake May Protect Against Prostate Cancer Progression, Recurrence
2024-03-31
in Prostate cancer

High Plant Intake May Protect Against Prostate Cancer Progression, Recurrence

High Plant Intake May Protect Against Prostate Cancer Progression, Recurrence Men with prostate cancer who consume the most plant-based foods have lower risks of disease progression and recurrence, investigators reported at American Society of Clinical Oncology’s (ASCO) 2023 Genitourinary Cancers Symposium in San Francisco, California. “We’ve known that diets that include vegetables, fruits, legumes, and […]

Continue reading
Preventing, Managing Hyperuricemia After Kidney Transplantation
2024-03-26
in Kidney transplantation

Preventing, Managing Hyperuricemia After Kidney Transplantation

Preventing, Managing Hyperuricemia After Kidney Transplantation Hyperuricemia frequently occurs after kidney transplantation. In a recent review published in Frontiers in Surgery, Chuan Hao, MD, and colleagues from The Second Hospital of Shanxi Medical University in Taiyuan, China, discussed traditional and novel risk factors for hyperuricemia and potential options for management. According to Dr Hao’s team, management […]

Continue reading
Delaying Localized Prostate Cancer Treatment Does Not Increase Death Risk
2024-03-22
in Urology

Delaying Localized Prostate Cancer Treatment Does Not Increase Death Risk

Delaying Localized Prostate Cancer Treatment Does Not Increase Death Risk Patients and clinicians choosing among active surveillance, radical prostatectomy, and radiation therapy for low- to favorable intermediate-risk localized prostate cancer no longer need to worry that a treatment delay will lead to death. At the 38th Annual Congress of the European Association of Urology (EAU23) […]

Continue reading
Shockwave Therapy for Erectile Dysfunction Gaining in Popularity, Despite Skepticism
2024-03-02
in Urology

Shockwave Therapy for Erectile Dysfunction Gaining in Popularity, Despite Skepticism

Shockwave Therapy for Erectile Dysfunction Gaining in Popularity, Despite Skepticism Off-label use of low-intensity extracorporeal shockwave therapy for treating erectile dysfunction (ED) is growing in popularity in the United States in part because of extensive advertising. Similar to what is used for treating kidney stones and gallstones, this approach may help men who cannot take […]

Continue reading

    Detecting creditable urology research centers of the world to increase scientific communications and exchange ideas and bringing modern technology and urology for further scientific activities of Iranian researchers,
    Training urology researchers,
    Finding new methods of diagnosing and treating urologic diseases, esp. urogenital cancers using Nano medicine technology,
    Applying stem-cell in treating urologic diseases,
    Cooperate with relevant national research, executive centers for conducting research in the field of urology,
    Promoting the awareness level of the public on urologic diseases for prevention, early diagnosis, timely treatment and decreasing complications, morbidity and mortality.

    ADDRESS

    Urology Research Center, Sina Hospital, Hassan Abad Sq., Imam Khomeini Ave., Tehran, Iran

    PHONE

    (+98) 6634 8560

    EMAIL

    urc@tums.ac.ir